SpaceX's Only Real Rival Record Backlog, an $8B Bet, and a 55% Drop

Welcome back to Alpha Stocks Daily 👋

While SpaceX soaks up every space headline, there's exactly one other Western company reliably putting payloads into orbit at high frequency — and it's publicly traded. It just posted record revenue and a record backlog, Wall Street sees ~70% upside, and it's making an audacious multi-billion-dollar bet to take on Starlink directly. It's also down more than 50% from its highs, loses money, and swings violently. This is a high-growth, high-volatility story, and today we'll give you both sides.

Today's ticker: Rocket Lab ($RKLB) — a ~$37B (large-cap, not mega-cap) end-to-end space company: it builds satellites, launches them, and now wants to operate its own constellations. The bull case is genuinely exciting. So are the risks. Let's dig in. 👇

This is the genuinely bullish part. Across ~18 analysts, the consensus is a "Buy," with an average 12-month target near $110 and a range of $64 to $150 — implying roughly 65–70% upside from the ~$65 price. Ratings skew heavily positive: about 15 Buy/Strong Buy, ~4 Hold, 0 Sell.

One honest caveat: that big "upside" exists partly because the stock has fallen so far. RKLB ran to ~$150 earlier this year and is now ~$65 — so targets set near the highs now look like huge upside. The Street is genuinely bullish, but read the number in context: it's a target on a stock that's already round-tripped.

Rocket Lab's edge is vertical integration — it doesn't just launch rockets, it builds the satellites too, which lets it eventually own and operate entire constellations at costs rivals can't match. Three engines:

The proof is in the backlog: $2.36 billion, up 137% YoY — record visibility — with 90+ launches booked and major defense wins, including a $397M Space Force SB-AMTI contract, a $266M suborbital missile-defense deal, and a $160M geostationary-satellite award.

Here's the transformative move the market is still digesting. In June, Rocket Lab agreed to acquire Iridium Communications in a cash-and-stock deal valued at roughly $8 billion (~$5.9B equity value; $27/share cash plus stock). Iridium brings a 66-satellite global network, 2.5M+ subscribers, and ~$870M in annual revenue — instantly turning Rocket Lab into a self-launching, vertically integrated space-comms operator positioned to compete with Starlink.

The upside is obvious: recurring revenue, a real constellation, and a direct path to becoming a "space applications" powerhouse. But be clear about the risk — this is a huge, complex bet: it's financed partly with a $3.6 billion bridge loan (new debt) plus stock (dilution), it doesn't close until mid-2027 (pending regulatory and shareholder approval), and integration synergies are years away and unproven. This deal is the RKLB thesis now — for better or worse.

The backdrop is a genuine tailwind. Space is now an explicit warfighting domain, and U.S. defense spending on space architecture — missile tracking, resilient constellations, responsive launch — is surging. Rocket Lab's U.S. clearances and flight heritage make it a prime beneficiary of Space Force and DoD contracts, and the broader LEO constellation buildout (commercial and sovereign) drives long-term demand for both launch and satellites. As the only proven high-frequency Western launcher outside SpaceX, its competitive moat is real.

Rocket Lab's Q2 (reported Aug 10) was operationally excellent but financially mixed. Revenue hit a record $234M (+62% YoY) and backlog set a record — but adjusted EPS of -$0.08 missed the -$0.06 estimate (a wider-than-expected loss), the company burned $84M of operating cash, and shares fell after the print as investors focused on the path to profitability. Q3 revenue is guided to another record ($250–265M). Management also confirmed Neutron Stage 1 hardware is targeting Q4 pad delivery. Note the funding reality: the $2.13B cash pile was boosted by a $1.53B equity raise — capital to fund growth, but dilutive.

Context is essential: RKLB is a beta ~3 rollercoaster. It ran to ~$150, crashed ~56%, bounced to ~$80 around August earnings, and has since pulled back to the low-to-mid $60s — yet it's still up ~290% over the past year. This is a momentum growth stock, not a stable compounder.

Rocket Lab is the real deal: the only proven high-frequency Western launcher besides SpaceX, with a record $2.36B backlog, a fortress defense-contract position, ~41% non-GAAP margins, and Wall Street targeting ~70% upside. For investors who want pure-play exposure to the multi-decade space buildout, there is no better public alternative — and the Iridium deal, if it works, could make this a vertically integrated space-comms giant.

But go in clear-eyed. This is a pre-profit, high-beta growth stock that's already round-tripped from $150 to $65, it burns cash and dilutes to fund its ambitions, and it's betting the company on an $8B acquisition and an unproven rocket. The bull case: buy a generational space franchise ~55% off its highs with the Street far above you. The bear case: profitability keeps slipping, the Iridium debt/dilution weighs, and Neutron slips. The decider is execution — Neutron's first flight and the Iridium close. A high-conviction, high-risk holding for believers who can stomach the volatility and size accordingly.

What we're watching next: Neutron's Q4 pad delivery and first-flight timeline, the Iridium deal's regulatory/shareholder path, cash burn, and Q3 results (Nov 16).

Trade smart, size your risk, and we'll see you tomorrow. 🚀